Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 9/2009

01-09-2009 | Breast Oncology

Factors Associated with Optimal Cosmetic Results at 36 Months in Patients Treated with Accelerated Partial Breast Irradiation (APBI) on the American Society of Breast Surgeons (ASBrS) MammoSite® Breast Brachytherapy Registry Trial

Authors: Sharad Goyal, MD, Atif J. Khan, MD, Frank Vicini, MD, Peter D. Beitsch, MD, Maureen Lyden, MS, Martin Keisch, MD, Bruce G. Haffty, MD

Published in: Annals of Surgical Oncology | Issue 9/2009

Login to get access

Abstract

Purpose

To evaluate factors associated with optimal cosmetic results at 36 months for early-stage breast cancer patients enrolled on the American Society of Breast Surgeons (ASBrS) MammoSite® Breast Brachytherapy registry trial.

Materials and Methods

1,440 patients (1,449 cases) with early-stage breast cancer undergoing breast-conserving therapy were treated with the MammoSite® radiation therapy system (RTS) brachytherapy catheter to deliver adjuvant accelerated partial breast irradiation (APBI) (34 Gy in 3.4-Gy fractions). Cosmetic outcome was evaluated at each follow-up visit and dichotomized as excellent/good or fair/poor. Median follow-up for surviving patients was 43.0 months (range 0–73.0 months).

Results

The percentage of patients with good/excellent cosmetic results at 12, 24, 36, and 48 months were as follows: 94.5% (n = 950/1,005), 93.8% (n = 781/833), 93.1% (n = 683/734), and 90.4% (n = 520/575), respectively. Three-year absolute rates of good/excellent cosmesis were as follows: breast-related wound infection (BWI) (83.3%) versus no BWI (94%), <7 mm skin spacing (87.5%) versus ≥7 mm skin spacing (93.6%). Using multiple regression analysis, factors predictive of worse cosmetic outcome at 36 months included smaller skin spacing [odds ratio (OR) 1.06, confidence interval (CI) 1.01–1.12] and BWI (OR 0.33, CI 0.16–0.70). A predictive model developed showed that presence of a BWI, use of chemotherapy, and skin spacing had the most effect on cosmetic outcomes. However, in patients that did not develop a breast infection, skin spacing and use of chemotherapy had the most effect on cosmesis.

Conclusion

APBI delivered by MammoSite® brachytherapy lead to good/excellent cosmesis in 93% of patients with 3-year follow-up. Breast wound infection, use of chemotherapy, and skin spacing were found to be the three most important predictors of cosmesis at 36 months in our cohort of patients.
Literature
1.
Vrieling C, Collette L, Fourquet A, et al. The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC “boost versus no boost” trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys. 1999;45:677–85.PubMed
2.
Vrieling C, Collette L, Fourquet A, et al. The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC ‘boost vs. no boost’ trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiother Oncol. 2000;55:219–32.PubMedCrossRef
3.
Farrow DC, Hunt WC, Samet JM. Geographic variation in the treatment of localized breast cancer. N Engl J Med. 1992;326:1097–101.PubMed
4.
Lazovich DA, White E, Thomas DB, Moe RE. Underutilization of breast-conserving surgery and radiation therapy among women with stage I or II breast cancer. JAMA. 1991;266:3433–8.PubMedCrossRef
5.
Mann BA, Samet JM, Hunt WC, et al. Changing treatment of breast cancer in New Mexico from 1969 through 1985. JAMA. 1988;259:3413–7.PubMedCrossRef
6.
Ballard-Barbash R, Potosky AL, Harlan LC, et al. Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J Natl Cancer Inst. 1996;88:716–26.PubMedCrossRef
7.
Athas WF, Adams-Cameron M, Hunt WC, et al. Travel distance to radiation therapy and receipt of radiotherapy following breast-conserving surgery. J Natl Cancer Inst. 2000;92:269–71.PubMedCrossRef
8.
Kelemen JJ, 3rd, Poulton T, Swartz MT, Jatoi I. Surgical treatment of early-stage breast cancer in the Department of Defense Healthcare System. J Am Coll Surg. 2001;192:293–7.PubMedCrossRef
9.
Schroen AT, Brenin DR, Kelly MD, et al. Impact of patient distance to radiation therapy on mastectomy use in early-stage breast cancer patients. J Clin Oncol. 2005;23:7074–80.PubMedCrossRef
10.
Whelan T, Levine M, Gafni A, et al. Mastectomy or lumpectomy? Helping women make informed choices. J Clin Oncol. 1999;17:1727–35.PubMed
11.
Vicini FA, Beitsch PD, Quiet CA, et al. First analysis of patient demographics, technical reproducibility, cosmesis, and early toxicity: results of the American Society of Breast Surgeons MammoSite breast brachytherapy trial. Cancer. 2005;104:1138–48.PubMedCrossRef
12.
Arthur DW, Vicini FA, Kuske RR, et al. Accelerated partial breast irradiation: an updated report from the American Brachytherapy Society. Brachytherapy. 2002;1:184–90.PubMedCrossRef
13.
Vicini F, Baglan K, Kestin L, et al. The emerging role of brachytherapy in the management of patients with breast cancer. Semin Radiat Oncol. 2002;12:31–9.PubMedCrossRef
14.
Keisch M, Vicini F, Kuske RR, et al. Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2003;55:289–93.PubMed
15.
Haffty BG, Goldberg NB, Rose M, et al. Conservative surgery with radiation therapy in clinical stage I and II breast cancer. Results of a 20-year experience. Arch Surg. 1989;124:1266–70.PubMed
16.
Wazer DE, Kaufman S, Cuttino L, et al. Accelerated partial breast irradiation: an analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose-rate interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2006;64:489–95.PubMed
17.
Polgar C, Sulyok Z, Fodor J, et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. J Surg Oncol. 2002;80:121–8; discussion 129.PubMedCrossRef
18.
Polgar C, Major T, Fodor J, et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumor bed boost after breast-conserving surgery: seven-year results of a comparative study. Int J Radiat Oncol Biol Phys. 2004;60:1173–81.PubMed
19.
Taylor ME, Perez CA, Halverson KJ, et al. Factors influencing cosmetic results after conservation therapy for breast cancer. Int J Radiat Oncol Biol Phys. 1995;31:753–64.PubMed
20.
Beadle GF, Silver B, Botnick L, et al. Cosmetic results following primary radiation therapy for early breast cancer. Cancer. 1984;54:2911–8.PubMedCrossRef
21.
Haffty BG, Vicini FA, Beitsch P, et al. Timing of chemotherapy after MammoSite radiation therapy system breast brachytherapy: analysis of the American Society of Breast Surgeons MammoSite breast brachytherapy registry trial. Int J Radiat Oncol Biol Phys. 2008;72:1441–8.PubMed
Metadata
Title
Factors Associated with Optimal Cosmetic Results at 36 Months in Patients Treated with Accelerated Partial Breast Irradiation (APBI) on the American Society of Breast Surgeons (ASBrS) MammoSite® Breast Brachytherapy Registry Trial
Authors
Sharad Goyal, MD
Atif J. Khan, MD
Frank Vicini, MD
Peter D. Beitsch, MD
Maureen Lyden, MS
Martin Keisch, MD
Bruce G. Haffty, MD
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 9/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0561-y

Other articles of this Issue 9/2009

Annals of Surgical Oncology 9/2009 Go to the issue

Breast Oncology

Clinical Significance of Axillary Microresiduals After Neoadjuvant Chemotherapy in Breast Cancer Patients with Cytologically Proven Metastases

Gastrointestinal Oncology

CRP Genetic Polymorphism Is Associated with Lymph Node Metastasis in Thoracic Esophageal Squamous Cell Cancer

Melanomas

The Contoured Staged Marginal and Central Surgical Excision Technique With En Face Histopathological Analysis: Useful Additions in the Armamentarium for Treating and Diagnosing Melanoma In Situ

Erratum

Importance of Early Splenectomy in Patients with Hepatosplenic T-Cell Lymphoma and Severe Thrombocytopenia

Endocrine Tumors

High Rate of Multifocality and Occult Lymph Node Metastases in Papillary Thyroid Carcinoma Arising in Thyroglossal Duct Cysts

Gastrointestinal Oncology

Reply to “Totally Laparoscopic Gastrectomy: A Reality for USA and Europe?” (ASO-2009-04-0501.R1)